Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23363 | OBSL1 | S029 | Human | Liver | HCC | 1.76e-12 | 7.15e-01 | 0.2581 |
23363 | OBSL1 | C21 | Human | Oral cavity | OSCC | 6.04e-14 | 5.92e-01 | 0.2678 |
23363 | OBSL1 | C30 | Human | Oral cavity | OSCC | 3.55e-09 | 6.77e-01 | 0.3055 |
23363 | OBSL1 | C08 | Human | Oral cavity | OSCC | 7.88e-03 | 1.87e-01 | 0.1919 |
23363 | OBSL1 | C09 | Human | Oral cavity | OSCC | 6.35e-17 | 6.77e-01 | 0.1431 |
23363 | OBSL1 | SYSMH3 | Human | Oral cavity | OSCC | 8.97e-03 | 1.44e-01 | 0.2442 |
23363 | OBSL1 | Dong_P1 | Human | Prostate | Tumor | 2.45e-08 | 4.26e-02 | 0.035 |
23363 | OBSL1 | Dong_P3 | Human | Prostate | Tumor | 3.26e-09 | 1.68e-01 | 0.0278 |
23363 | OBSL1 | Dong_P5 | Human | Prostate | Tumor | 2.83e-14 | 1.09e-01 | 0.053 |
23363 | OBSL1 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 1.15e-05 | 5.88e-01 | 0.1557 |
23363 | OBSL1 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 6.60e-09 | 5.53e-01 | 0.1633 |
23363 | OBSL1 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.83e-15 | 6.52e-01 | 0.1608 |
23363 | OBSL1 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 9.06e-08 | 5.60e-01 | 0.1604 |
23363 | OBSL1 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 5.96e-06 | 4.70e-01 | 0.1621 |
23363 | OBSL1 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 4.99e-06 | 4.67e-01 | 0.1619 |
23363 | OBSL1 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 9.18e-06 | 7.17e-01 | 0.159 |
23363 | OBSL1 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 5.06e-05 | 4.24e-01 | 0.1602 |
23363 | OBSL1 | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 1.01e-02 | 4.77e-01 | 0.1439 |
23363 | OBSL1 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 2.44e-07 | 6.57e-01 | 0.1608 |
23363 | OBSL1 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 2.45e-13 | 1.03e+00 | 0.1622 |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/OBSL1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/OBSL1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/OBSL1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/OBSL1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/OBSL1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
GO:00070883 | Esophagus | ESCC | regulation of mitotic nuclear division | 78/8552 | 110/18723 | 6.96e-08 | 1.21e-06 | 78 |
GO:00070308 | Esophagus | ESCC | Golgi organization | 101/8552 | 157/18723 | 1.78e-06 | 2.10e-05 | 101 |
GO:00517831 | Esophagus | ESCC | regulation of nuclear division | 90/8552 | 139/18723 | 4.30e-06 | 4.60e-05 | 90 |
GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
GO:001072010 | Esophagus | ESCC | positive regulation of cell development | 172/8552 | 298/18723 | 1.74e-05 | 1.55e-04 | 172 |
GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
GO:00507697 | Esophagus | ESCC | positive regulation of neurogenesis | 131/8552 | 225/18723 | 9.71e-05 | 6.90e-04 | 131 |
GO:00340676 | Esophagus | ESCC | protein localization to Golgi apparatus | 23/8552 | 29/18723 | 2.25e-04 | 1.40e-03 | 23 |
GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
GO:001076920 | Esophagus | ESCC | regulation of cell morphogenesis involved in differentiation | 61/8552 | 96/18723 | 3.12e-04 | 1.85e-03 | 61 |
GO:00519606 | Esophagus | ESCC | regulation of nervous system development | 237/8552 | 443/18723 | 5.02e-04 | 2.78e-03 | 237 |
GO:001077018 | Esophagus | ESCC | positive regulation of cell morphogenesis involved in differentiation | 51/8552 | 79/18723 | 5.48e-04 | 3.00e-03 | 51 |
GO:00519625 | Esophagus | ESCC | positive regulation of nervous system development | 149/8552 | 272/18723 | 1.50e-03 | 7.06e-03 | 149 |
GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OBSL1 | SNV | Missense_Mutation | | c.2265G>T | p.Lys755Asn | p.K755N | O75147 | protein_coding | tolerated(0.28) | benign(0.142) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
OBSL1 | SNV | Missense_Mutation | novel | c.1249N>G | p.Arg417Gly | p.R417G | O75147 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
OBSL1 | SNV | Missense_Mutation | rs768834976 | c.2161N>A | p.Gln721Lys | p.Q721K | O75147 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
OBSL1 | SNV | Missense_Mutation | | c.2407N>A | p.Asp803Asn | p.D803N | O75147 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
OBSL1 | SNV | Missense_Mutation | rs757910265 | c.3254N>A | p.Ala1085Glu | p.A1085E | O75147 | protein_coding | tolerated(0.99) | possibly_damaging(0.741) | TCGA-AC-A2QJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
OBSL1 | SNV | Missense_Mutation | rs757910265 | c.3254N>A | p.Ala1085Glu | p.A1085E | O75147 | protein_coding | tolerated(0.99) | possibly_damaging(0.741) | TCGA-AC-A3QP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
OBSL1 | SNV | Missense_Mutation | rs765704645 | c.4766C>T | p.Ser1589Leu | p.S1589L | O75147 | protein_coding | tolerated(0.05) | benign(0.021) | TCGA-AC-A6IV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
OBSL1 | SNV | Missense_Mutation | | c.4189N>A | p.Ala1397Thr | p.A1397T | O75147 | protein_coding | tolerated(0.51) | benign(0.01) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OBSL1 | SNV | Missense_Mutation | novel | c.2329G>C | p.Glu777Gln | p.E777Q | O75147 | protein_coding | tolerated(0.11) | benign(0.328) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
OBSL1 | SNV | Missense_Mutation | rs757910265 | c.3254N>A | p.Ala1085Glu | p.A1085E | O75147 | protein_coding | tolerated(0.99) | possibly_damaging(0.741) | TCGA-BH-A5J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |